GSK3B and autoimmune thrombocytopenic purpura: This study aimed to evaluate the expression of GSK‐3β in monocytes in ITP patients, to examine the regulating effects of the novel GSK‐3βi YC‐4‐3 on macrophages in ITP, to explore the specific mechanisms of GSK‐3β, and to provide evidence for YC‐4‐3, this novel GSK‐3βi as a new potential therapeutic target for ITP, and to investigate its unique mechanism in the treatment of ITP.